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PENILAIAN JANGKITAN DENGGI: PENENTUAN FAKTOR-FAKTOR 
RISIKO DAN TERHASILNYA KECACATAN GINGAL AKUT DI 
HOSPITAL UNIVERSITI SAINS MALAYSIA 
ABSTRAK 
Walaupun pelbagai tindakan agresif telah diambil oleh pihak berkuasa 
tempatan, Malaysia masih menghadapi krisis denggi yang semakin buruk beberapa 
tahun kebelakang ini. Ini menunjukkan langkah-langkah segera diperlukan untuk 
menilai kes denggi bagi memahami spektrum klinikal-makmal untuk menghadapi 
penyakit ini. Tambahan pula, data terkini menunjukkan laporan semakin meningkat 
ke atas kecederaan gingal akut (AKI) kalangan pesakit denggi. Walaupun bukti 
ketara menunjukkan peningkatan sementara dalam kreatinin serum (SCr) yang 
dikaitkan dengan peningkatan morbiditi dan mortaliti, AKI masih lagi tergolong 
dalam komplikasi yang diabaikan dalam denggi. Terdapat kekurangan siasatan 
epidemiologi denggi-aruhan AKI (DAKI). Malangnya, tidak ada laporan mengenai 
DAKI di Malaysia. Di samping itu, data pasca AKI pemulihan renal juga kurang. 
Oleh itu, dua kajian fasa retrospektif dan prospektif dijalankan untuk menilai ciri-ciri 
klinikal-makmal dan peramal bagi demam denggi berdarah (DHF) dan untuk menilai 
epidemiologi AKI semasa dan selepas discaj daripada hospital. Semasa Fasa-I 
(retrospektif), sejumlah 667 pesakit denggi telah dikaji semula dan DHF diperhatikan 
dalam 79 kes (11.8%). Analisis regresi multivariat menunjukkan kehadiran umur 
melebihi  40 tahun (OR: 4,1), jangkitan sekunder (OR: 2.7), kencing manis (OR: 
2,8), lesu (OR: 3.1), pundi hempedu tebal (OR: 1.7) dan terlewat dimasukkan ke 
hospital (OR: 2.3) sebagai peramal bebas bagi DHF. Keseluruhan mortaliti adalah 
1.2% dan hampir separuh daripada pesakit-pesakit telah menginap lama di hospital 
 xv 
(≥3 hari). Beberapa faktor berkaitan hospitalisasi berpanjangan dan mortaliti juga 
telah dinilai dalam fasa retrospektif. Prevalens AKI adalah 14.2% mengikut kriteria 
oleh AKIN, 12.6% oleh RIFLE dan 4.2% dengan takrifan konvensional. Kehadiran 
DHF (OR 8.0), rabdomiolisis (OR 7.9), disfungsi organ berganda (OR: 17.9), 
diabetes (OR 4.7), hospitalisasi lewat (OR: 2.1) dan penggunaan ubat-ubatan 
nefrotoksik (OR: 2.9) adalah berkaitan dengan AKI. Tambahan pula, pesakit dengan 
AKI disahkan mempunyai morbiditi signifikan, mortaliti, dan lebih lama tinggal di 
hospital. Semasa (prospektif) kajian Fasa-II, 526 pesakit telah diuji dan AKI 
diperhatikan dalam 13.7% kes. Pemulihan renal telah dinilai kalangan mangsa AKI 
(n = 71) pada tempoh 6 minggu dan minggu ke-12 dengan menggunakan beberapa 
kriteria pemulihan. Dengan menggunakan takrifan ketat bagi pemulihan renal 
daripada kurang (pemulihan ± 50% kepada garis dasar) kepada lebih (± 5% 
pemulihan ke garis dasar) menunjukkan kadar pemulihan daripada 88.9% kepada 
2.8% bagi SCR dan 94.4% kepada 5.6% bagi eGFR, sebagai penanda bio bagi fungsi 
renal.. Pada akhir kajian, lapan pesakit mempunyai AKI dengan 7 daripadanya 
mengikut AKIN-II dan seorang pesakit bagi AKIN-III. Pesakit tua dengan ko-
morbiditi, MODS dan penggunaan ubat-ubatan nefrotoksik ketika di hospital 
mempunyai hasil renal yang lemah bagi kriteria pemulihan renal yang digunakan. 
Kajian ini menunjukkan bahawa DF dan DHF mempunyai perbezaan profil klinikal-
makmal yang ketara. Sebaliknya, AKI hadir dalam sebahagian besar pesakit denggi 
dan mereka yang mempunyai AKI menandakan morbiditi yang signifikan, mortaliti 
dan hospitalisasi yang lama. Pengenalpastian awal pesakit-pesakit yang berisiko 
tinggi akan mempunyai kelebihan yang jelas dari segi keputusan yang sesuai tentang 
rawatan dan pengurusan dalam unit pergantungan tinggi. Selain itu, jangkitan denggi 
AKI menunjukkan hasil renal yang tidak memuaskan dan memerlukan penjagaan 
 xvi 
dan susulan yang lebih lama, terutama di bawah penjagaan nefrologi. Terdapat 
keperluan untuk melakukan kajian lanjutan di pelbagai pusat dengan tempoh susulan 
yang lebih penjang untuk mengesahkan penemuan kajian ini serta menjelaskan 
pengunaan kriteria bagi pemulihan renal pada pesakit-pesakit denggi.  
 xvii 
EVALUATION OF DENGUE INFECTION: DETERMINATION OF RISK 
FACTORS AND OUTCOMES OF ACUTE KIDNEY INJURY IN HOSPITAL 
UNIVERSITI SAINS MALAYSIA 
ABSTRACT 
Despite aggressive measures taken by the relevant authorities, Malaysia is still 
facing worsening dengue crisis over the past few years. It warrants an urgent need to 
evaluate dengue cases for better understanding of clinico-laboratory spectrum in 
order to combat this disease. Moreover, recent data indicate the increasing reports on 
acute kidney injury (AKI) among dengue patients. Despite notable evidence that 
transient increase in serum creatinine (SCr) is linked to increased morbidity and 
mortality, AKI is still a neglected complication of dengue. There has been a dearth of 
investigation on epidemiology of dengue-induced AKI (DAKI). Unfortunately, there 
is no report on DAKI in Malaysia.  In addition, the data on post-AKI renal recovery 
is currently lacking. Therefore, two phase retrospective and prospective study was 
conducted to evaluate the clinico-laboratory characteristics and predictors of dengue 
hemorrhagic fever (DHF) and to assess epidemiology of AKI and post-AKI renal 
recovery among patients attending Hospital Universiti Sains Malaysia (HUSM). 
During Phase-I (retrospective), a total 667 dengue patients were reviewed. DHF was 
observed in 79 (11.8 %) cases. Multivariate regression analysis demonstrated 
presence of age > 40 years (OR: 4.1), secondary infection (OR: 2.7), diabetes 
mellitus (OR: 2.8), lethargy (OR: 3.1), thick gallbladder (OR: 1.7) and delayed 
hospitalization (OR: 2.3) as independent predictors of DHF. Overall mortality was 
1.2 % and approximately half of the patients had prolonged hospital stay (≥3 days). 
Several factors associated with prolonged hospitalization and mortality have also 
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evaluated in retrospective phase. The prevalence of AKI was 14.2% by AKIN (Acute 
Kidney Injury Network) criterion, 12.6% by RIFLE (Risk, Injury, Failure, Loss of 
function, End stage renal disease) and 4.2% with conventional definition. Presence of 
DHF (OR: 8.0), rhabdomyolysis (OR: 7.9), multiple organ dysfunction (OR: 17.9), 
diabetes mellitus (OR 4.7), late hospitalization (OR: 2.1) and use of nephrotoxic 
drugs (OR: 2.9) were associated with AKI.  Additionally, patients with AKI had 
significant morbidity, mortality and longer hospital stay. During Phase-II 
(prospective) study, 13.7% of 526 patients had AKI. Renal recovery was assessed 
among AKI survivors (n=71) after twelve weeks by using several criteria of 
recovery. The use of less (± 50% recovery to baseline) to more (± 5% recovery to 
baseline) stringent definitions of renal recovery demonstrated recovery rates from 
88.9% to 2.8% by SCr and 94.4% to 5.6% by eGFR, as renal function biomarker. At 
the end of study, eight patients had AKI with AKIN-II in 7 and AKIN-III in one 
patient. Elderly patients with comorbidities, multiple organ dysfunctions and use of 
nephrotoxic drugs during hospitalization had poor renal outcomes with either 
criterion of renal recovery. Current study demonstrated that DF and DHF present 
significantly different clinico-laboratory profile. On the other hand, AKI is present in 
substantial proportion of dengue patients and those with AKI portended significant 
morbidity, mortality and prolonged hospitalization.  Early identification of high risk 
patients will have obvious advantages in terms of appropriate decisions about 
treatment and management in high dependency units. Moreover, AKI in dengue 
infection indicates unsatisfactory renal outcomes and deserve a careful and longer 
follow-up, especially under nephrology care. There is a need for appropriately 
powered multi-center trials with longer follow-up period to validate the research 
findings and to clarify the utility of criteria for renal recovery in dengue patients.
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CHAPTER 1 
INTRODUCTION 
1.1 Dengue Viral Infection (DVI) 
Dengue viral infection (DVI) is a dangerous, debilitating and among the most 
important arthropod-borne disease that has rapidly been spread in several regions of 
the world in recent years (Messina et al., 2014). The disease is widespread 
throughout the tropics, with local variations in risk, influence by rainfall, temperature 
and unplanned rapid urbanization. The spectrum of disease varies from mild self-
limiting illness, dengue fever (DF) to more severe and fulminating forms, dengue 
hemorrhagic fever (DHF) and dengue shock syndrome (DSS) (Deen et al., 2006). 
1.1.1 Dengue Virus, Vector and Host 
Dengue infections are believed to be caused by dengue virus (DENV), 
a mosquito-borne single positive stranded RNA virus (family: Flaviviridae, 
genus Flavivirus). There are four related but antigenically distinct serotypes of 
dengue virus designated as DENV-1, DENV-2, DENV-3, and DENV-4 (Khan et al., 
2008). These four serotypes are genetically similar and share approximately 65% of 
their genomes (Gubler, 2002). However, fifth serotype (DENV-5) has been detected 
during the screening of viral samples in Sarawak state of Malaysia and announced in 
October 2013 (Normile, 2013). Dengue virus is transmitted to non-human primates 
(sylvatic form) and humans (human form) via a mosquito vector; primarily of the 
genus Aedes (Subgenus: Stegomyia). The two most prominent species responsible for 
DENV transmission are Aedes aegypti (Origin: Africa) and Aedes albopictus (Origin: 
Asia) (Mustafa et al., 2015). The first infection by one serotype produces life long, 
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serotype-specific immunity but not lasting protection against infection by another 
serotype. Humans are the main amplifying host of the virus that is transmitted to 
them by the bite of an infective mosquito. The virus undergoes an intrinsic 
incubation period (IIP - time taken by the virus to complete its development in 
humans/animals) of 3 to 14 days (average, 4 to 7 days), after which the person may 
experience acute onset of fever accompanied by a variety of nonspecific signs and 
symptoms. During this acute febrile period (2 – 10 days) dengue viruses may 
circulate in the peripheral blood. This human febrile viremic phase (2 days before 
and 4-5 days after onset of fever) is a source of viruses for other mosquitoes. Dengue 
virus circulating in the blood of viremic humans is ingested by female mosquitoes 
during feeding. The virus then infects the mosquito mid-gut and subsequently 
spreads systemically over a period of 8 – 12 days. After this extrinsic incubation 
period (EIP - time taken by the virus to complete its development in mosquitos), the 
virus can be transmitted to other humans during subsequent probing or feeding. The 
EIP is influenced in part by environmental conditions, especially ambient 
temperature. Thereafter the mosquito remains infective for the rest of its life 
(WHO/SEARO, 2011).  
Aedes aegypti is a small, dark mosquito that can be identified by the white 
bands on its legs and white lyre shaped markings on its body. It is highly resilient 
with the ability to rapidly bounce back to initial numbers after disturbances caused 
by the natural disaster or human interventions. Aedes albopictus, also known as 
Asian tiger mosquito, is also a small, dark mosquito with a white dorsal stripes and 
banded legs. It is slightly hardier than Aedes aegypti and feeds both on human and 
animals (Jansen & Beebe, 2010). Both vectors differ characteristically from each 
other as summarized in Table 1.1.  
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Table 1.1: Characteristics of two major species of Aedes vector  
Aedes aegypti Aedes albopictus 
 Origin: Africa  Origin: Asia 
 Highly domesticated  Maintain feral moorings 
 Strong antrhopophilic1  Feeds on both human and 
animals 
 Nervous feeder2  Aggressive feeder4 
 Discordant species3  Concordant species5 
 High vectorial competency  High vectorial competency 
 Strong vectorial capacity in 
urban areas while poor in rural 
regions 
 Poor vectorial capacity in 
urban areas while strong in 
rural regions 
1
prefer human beings over animals 
2
bite more than one host to complete one blood meal 
3
need more than one meal for completion of gonotropic cycle 
4
complete blood meal in one person in one go 
5
doest not require second blood meal for completion of gonotropic cycle 
Reference: (WHO/SEARO, 2011) 
1.1.2 Transmission of dengue virus 
The transmission of DENV occurs in three cycles including enzootic (a 
primitive sylvatic cycle by monkeys-Aedes-monkeys), epizootic (crosses over to 
non-human primates from adjoining human epidemic cycles) and epidemic cycle 
(human-Aedes-human). After ingestion of blood from human, virus replicates in 
epithelial cell lining of mid-gut and infects the salivary glands. Afterwards, 
infectious saliva transmitted to human primates during probing. DENV also infect 
genital tract and may enter to fully developed eggs (De-Silva et al., 1999). Dengue 
transmission usually occurs during rainy season when temperature and humidity are 
more suitable for vector population breeding, while in regions where rainfall is 
scanty, vector breeds in man-made storage containers. However, during dry season, 
the life cycle of Aedes aegypti hastens that result in small-size mosquitos and shorter 
EIP. Small size females are required to take more blood meals for protein needed for 
egg production, thereby increasing the number of bites and hence infected 
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individuals.  Urbanization and increased global travels are some other factors 
promoting vector breed, thus resulting in high transmission potential (WHO/SEARO, 
2011). 
1.2 Clinical course of Dengue Infection 
After the incubation period, the illness often begins abruptly with fever and 
follows three phases i.e. febrile, critical and recovery phase (Figure 1.1) (WHO, 
2009; Mustafa & Bee, 2011, CDC, 2014; Clinical Practice Guidelines Malaysia, 
2015). The hallmark features of febrile phase include onset of symptoms along with 
viremia-derived high grade fever. Critical phase, also termed as plasma leak phase, is 
characterized by sudden onset of varying degrees of plasma leak into the pleural and 
abdominal cavities. Recovery phase, also refer as convalescence or reabsorption 
phase, is a sudden arrest of plasma leak with concomitant reabsorption of 
extravasated plasma and fluids (CDC, 2014). The characteristics, clinical 
manifestations, laboratory findings and complications of each phase have been 
described below. 
 
Figure 1.1: Three Phases during clinical course of dengue infection  
Descriptive note: Figure is reprinted from (CDC, 2014) – Centers for Disease Control and 
Prevention, Dengue Clinical Case management. Version 1.1, March, 2014  
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1.2.1 Febrile phase 
1.2.1(a) Characteristics 
Typical duration for this phase ranges from 0 to 7 days and biphasic fever can 
occur. Monitoring of defervescence (may occur between 3-8 days of illness) and 
warning signs is crucial to identify progression to critical phase (CDC, 2014).  
1.2.1(b) Clinical Manifestations during Febrile Phase 
This phase is often accompanied by onset of high temperature plus severe 
headache, retro-orbital pain, myalgia, arthralgia, transient macular or maculopapular 
rash, facial flushing or erythema, injected oro-pharynx, nausea, vomiting, anorexia, 
and minor hemorrhagic manifestations such as petechia, ecchymosis, purpura, 
epistaxis, gum bleeding, hematuria, vaginal and gastrointestinal bleeding or positive 
tourniquet test. Liver may be large or tender after few days of fever. Onset of fever 
may also cause limited daily activity (CDC, 2014; WHO/SEARO, 2011). 
1.2.1(c) Laboratory Findings during Febrile Phase 
Leucopenia, mild to moderate thrombocytopenia, hyponatremia and elevated 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) can occur 
during this phase (CDC, 2014; WHO/SEARO, 2011). 
1.2.1(d) Complications during Febrile Phase 
Febrile phase may cause several complications such as dehydration, 
hyponatremia; seizures in young children (due to fever) and neurological 
manifestations (encephalitis and aseptic meningitis) (CDC, 2014; WHO/SEARO, 
2011). 
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1.2.2 Critical Phase 
1.2.2(a) Characteristics 
This phase typically starts around the time of defervescence; however, it may 
begin early among patients who are febrile on third day of onset of fever and lasts 
about 24 – 48 hours. During the febrile to afebrile transition, patients without 
increased capillary permeability improve and do not go through the critical phase. On 
the other hand, patients with increased capillary permeability may manifest with the 
warning signs, primarily due to plasma leakage.  Onset of critical phase can be 
identified by rapid decline in platelet (PLT) count with a rise in hematocrit (HCT) 
and presence of warning signs for severe disease. Moreover, patients may develop 
leucopenia up to 24 hours before platelet drop is recognized (CDC, 2014; 
WHO/SEARO, 2011). The presence of warning signs indicates the beginning of 
critical phase. Therefore, the following warning signs should be observed before or 
at the time of defervescence during dengue infection (CDC, 2014). 
 Clinical fluid accumulation (ascites, pleural effusion) 
 Liver enlargement > 2 cm 
 Severe abdominal pain or tenderness 
 Persistent vomiting (at least 3 episodes/24 hours) 
 Mucosal bleed 
 Lethargy or restlessness 
 Sometimes rapid decline in PLT count with concurrent increase hematocrit in 
(HCT) is also considered warning sign 
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1.2.2(b) Clinical Manifestations during Critical Phase 
Progressive leukopenia followed by a rapid reduction in PLT count and 
increased HCT above baseline usually precedes plasma leakage. The degree of 
plasma leakage varies and usually reflected with the degree of hemoconcentration (as 
determined by elevated HCT). However, degree of hemocentration is affected by 
intravenous fluid (IVF) therapy. An early IV therapy can reduce hemoconcentration; 
therefore, frequent monitoring of HCT levels is essential for the adjustment of IVF 
therapy.  Pleural effusion and ascites are usually only clinically detectable after IVF 
therapy, unless plasma leakage is significant. In addition to the plasma leakage, 
hemorrhagic manifestations such as easy bruising and bleeding at venipuncture sites 
occur frequently (CDC, 2014; WHO/SEARO, 2011). 
In most of the cases with plasma leakage, circulatory changes are minimal or 
transient and many of these patients recover spontaneously or after fluid/electrolyte 
therapy. However, patients with severe plasma leakage may develop shock due to 
loss of critical plasma volume. With profound and/or prolonged shock, 
hypoperfusion results in metabolic acidosis, progressive organ impairment, and 
disseminated intravascular coagulation (DIVC) which lead to severe hemorrhage 
causing reduced HCT in severe shock. Instead of the leukopenia usually seen during 
this phase of dengue, the total white cell count (WBCs) may increase as a stress 
response in patients with severe bleeding. In addition, severe organ involvement may 
develop. Some patients progress to the critical phase of plasma leakage and shock 
before defervescence (WHO/SEARO, 2011). 
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1.2.2(c) Laboratory findings during Critical Phase 
Critical phase causes marked disturbances in laboratory parameters that include 
increased HCT (hemocentration), moderate to severe thrombocytopenia, leukopenia 
and transient increase in activated partial-thromboplastin time (aPTT) with decrease 
in fibrinogen (WHO/SEARO, 2011). 
1.2.2(d) Complications during Critical Phase 
Hypovolemic shock from plasma leakage, end organ impairment due to 
prolonged shock, severe hemorrhage and encephalopathy are some major 
complications during critical phase (WHO/SEARO, 2011). 
1.2.3 Recovery Phase 
1.2.3(a) Characteristics 
If patient survives critical phase, a gradual reabsorption of extravascular fluid 
in next 48 to 72 hours. However, recovery depends on the severity of illness and 
treatments provided during febrile and critical phase (CDC, 2014).  
1.2.3(b) Clinical Clues (Manifestations) of Recovery Phase 
Clinical clues of recovery phase include patient`s improvement, hemodynamic 
stability, fatigue and increased diuresis. Moreover, second rash that might be macular 
or erythematous with small circular islands of normal, unaffected skin. This 
convalescent rash can be very pruritic and desquamate. Bradycardia and 
electrocardiographic changes are common during this stage. Moreover, patients may 
experience severe fatigue during this phase (CDC, 2014). 
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1.2.3(c) Laboratory Findings during Recovery Phase 
Stable HCT or slightly elevated due to dilutional effect of reabsorbed plasma 
(hemodilution), rise in WBCs soon after defervescence, increase PLT after WBC 
recovery 
1.2.3(d) Complications during Recovery Phase 
Respiratory distress may occur from massive pleural effusion and ascites. 
Hypervolemia, congestive heart failure (CHF) and acute pulmonary edema can occur 
if IVF therapy has been excessive or extended too long. Organ impairment can result 
due to prolonged or refractory shock. This might include ischemic hepatitis and 
hepatic encephalopathy. Nosocomial  infections can occur, especially in infants and 
elderly patients. All the three phase of clinical course of dengue infection are 
characterized by specific clinico-laboratory features and serology and virology 
pattern. Summary of the clinical course of DVI is presented in Figure 1.2. 
 
Figure 1.2: Summary of Clinical Course of Dengue Infection  
Descriptive note: Figure is reprinted from (CPG, 2015) – Clinical Practice Guidelines of Malaysia on 
Dengue management  
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1.3 Diagnosis of Dengue Infection 
Dengue can be diagnosed either by isolation of virus or by serological and 
molecular methods. Early and accurate diagnosis of DVI is of paramount importance 
for surveillance, management, trials, research and detection of circulating serotypes. 
Diagnostic tests used to confirm DVI are described in Table 1.2 (Clinical Practice 
Guidelines, 2015). The use of diagnostic tests varies among hospitals depending 
upon the availability and nature of dengue infection. However, diagnostic tests 
include point of care testing such as dengue NS1 antigen test and rapid combo tests 
(NS1 antigen and dengue IgM/IgG antibodies) (Blacksell et al., 2011).  
Dengue rapid combo test (NS1 and IgM) or NS1 antigen should be carried out 
among suspected cases. However, type of diagnostic test should be based on 
patient`s clinical history (Clinical Practice Guidelines, 2015). Table 1.3 demonstrates 
the recommendations of diagnostic tests according to the clinical history of patients.  
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Table 1.2: Types of Diagnostic tests for Dengue Infection 
Technique Recommended time, Specificity and Sensitivity 
Antibody detection 
IgM detection 4 days after onset of symptoms and up to 3 months in primary 
dengue. 3 days after onset of symptoms and sometimes 
hindered by large scale IgG production in secondary dengue 
(Sensitivity: 61.5-100%, Specificity: 52-100%) 
IgG detection 10 days after onset of symptom in primary dengue and 3 days 
after onset of symptoms in secondary dengue (Sensitivity: 
46.4-99%, Specificity: 80-100%) 
Rapid IgM 
detection (Strips) 
5 days after onset of symptoms and up to 2 months (Sensitivity: 
20.5-97.7%, Specificity: 76.6-96.6%) 
Antigen/ Antibody Combined Detection 
NS1 and IgM 
Combo Kit  
As this is a combo test, useful in early stage of infection (day 3 
onwards) and up to sero-conversion period (up to two weeks 
onwards) (Sensitivity: 89.9-92.9%, Specificity: 75-100%) 
NS1 and IgM/IgG 
Combo kit 
As this is a combo test, useful in early stage of infection (day 3 
onwards) and up to sero-conversion period (up to two weeks 
onwards). In the event of both NS1 and IgM are non-reactive 
and IgG is reactive, case can be interpreted as secondary 
dengue. (Sensitivity: 93%, Specificity: 100%) 
Viral Detection 
Virus Isolation 
(cell culture) 
1-5 days of onset of symptoms in Primary Dengue and 1-4 days 
after onset of symptoms in secondary dengue (Sensitivity: 
40.5%, Specificity: 100%) 
Virus Isolation 
(mosquitoes) 
Same as above, (Sensitivity: 71.5-84.2%, Specificity: 100%) 
Viral RNA RT-
PCR 
(Conventional) 
Same as above, (Sensitivity: 48.4-100%, Specificity: 100%) 
Viral RNA RT-
PCR (Real Time) 
Same as above, (Sensitivity: 58.9-100%, Specificity: 100%) 
Viral Antigen 
(NS1)  
1-7 days of onset of symptoms in primary dengue and 1-5 days 
after onset of symptoms in secondary dengue (Sensitivity: 
54.2-93.4%, Specificity: 92.5-100%) 
Abbreviations: IgM: immunoglobulin M, IgG: immunoglobulin G, NS1: non-
structural protein 1, RNA: ribonucleic acid, RT-PCR: reverse transcriptase 
polymerase chain reaction 
 
Reference: Malaysian Clinical Practice Guidelines on Dengue Infection (2015) 
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Table 1.3: Recommendation of type of dengue test based on Clinical History of 
Patients and interpretation of their results 
Clinical History 
(Test) 
Results Interpretations 
Fever < 5 days 
(Dengue NS1 or 
RCT) 
Positive Acute dengue infection 
Negative DVI still cannot rule out. Repeat for Dengue 
IgM after day 5 of fever 
Fever >5 days 
(Dengue IgM) 
 
Positive Suggestive of recent dengue infection 
Intermediate Repeat 
Negative The result does not rule out dengue infection. 
Repeat sample for dengue IgM after day 7 of 
fever or dengue IgG test. 
Fever > 5 days and 
Dengue IgM and/or 
NS1 was negative 
(Dengue IgG) 
Positive Elevated IgG levels are seen in acute or past 
infections. A titre of ≥ 1:2560 is consistent 
with acute secondary infection 
Intermediate Repeat if clinically indicated 
Negative The absence of elevated IgG is presumptive 
evidence that the patient does not have 
secondary dengue infection.  
Abbreviations: NS1: non-structural protein 1, RCT: rapid combo test, DVI: dengue 
viral infection, IgM: immunoglobulin M, IgG: immunoglobulin G 
 
Reference: Malaysian Clinical Practice Guidelines on Dengue Infection (2015) 
1.4 Dengue Case Classification 
The World Health Organization (WHO) in 1997 classified DVI as 
undifferentiated fever, dengue fever (DF) and dengue hemorrhagic fever (DHF), 
where DHF was further divided into four grades (Grade I-IV). Grades III and IV are 
referred to as dengue shock syndrome (DSS) (WHO, 1997). In 2009, WHO proposed 
new classification of DVI due to complexity and applicability of previous 1997 
criteria. According to new definition, dengue severity is divided into non-severe 
(dengue with and without warning signs) and severe dengue (WHO, 2009). 
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However, older classification is still widely used, as WHO`s regional office for 
South-East Asia (SEARO) has included 1997 definition in its revised and expanded 
guidelines for DVI (WHO/SEARO, 2011). Although, there is move towards using 
the 2009 classification due to its ease of use but WHO still favors both case 
definitions. Nevertheless, there has been a considerable debate regarding the value of 
both 1997 and 2009 classifications (Hadinegoro, 2012). More recently, centers of 
disease control and prevention (CDC) classified DVI into three types i.e. dengue, 
dengue like illness and severe dengue. Dengue like illness is defined by fever and 
included in the list of notifiable infectious conditions (CDC, 2015). The use of 
criteria for dengue classification depends on discretion of treating physician and 
hospital or national dengue guidelines. The details of WHO and WHO/SEARO 
criteria is given below.  
1.4.1 Dengue Case Classification (WHO, 2009) 
This classification provides information to identify probable and confirm 
dengue cases that can further be classified into severe and non-severe dengue 
infection as demonstrated by Figure 1.3 (WHO, 2009). 
1.4.2 Dengue Case Classification (WHO/SEARO, 2011) 
The regional office of WHO for South-East Asia (SEARO) has revised dengue 
guidelines in 2011 and classified DVI into asymptomatic infection, viral syndrome, 
dengue fever (DF) and dengue hemorrhagic fever (DHF) including dengue shock 
syndrome (DSS) (Figure 1.4). However, the classification used in these 
contemporary guidelines corresponds to WHO 1999 criteria (WHO/SEARO, 2011).  
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Figure 1.3: WHO 2009 Criteria for dengue Classification 
Descriptive note: Figure is reprinted from (WHO, 2009) – World health Organization. Dengue 
Guidelines for Diagnosis, Treatment, Prevention and Control 
 
 
Figure 1.4: WHO/SEARO 2011 or WHO 1999 criteria for dengue classification  
Descriptive note: Figure is reprinted from (WHO/SERAO, 2011) – Comprehensive guidelines for 
prevention and control of dengue and dengue hemorrhagic fever 
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The severity of DHF is classified into four grades (Table 1.4) where presence of 
thrombocytopenia with concurrent hemoconcentration differentiates Grade I and 
Grade II from dengue fever. Grading the severity of the disease has been found 
clinically and epidemiologically useful in both children and adults.  
Table 1.4: Classification of dengue viral infection according to WHO/SEARO 
(2011) 
DVI classification Sign and Symptoms Laboratory findings 
DF Fever with two of the following: 
 Headache 
 Retro-orbital pain 
 Myalgia 
 Arthralgia/bone pain 
 Rash 
 Hemorrhagic manifestations 
 No evidence of plasma 
leakage 
Leucopenia (WBC ≤5000 
cells/mm3) 
Thrombocytopenia (Platelet 
Count <150 000 cells/mm3) 
Rising hematocrit (5% – 
10%) 
No evidence of plasma loss 
DHF (Grade I) Fever and hemorrhagic 
manifestation (positive 
tourniquet test) and evidence of 
plasma leakage 
Thrombocytopenia <100 000 
cells/mm3; HCT rise ≥20% 
DHF (Grade II) As in Grade I plus spontaneous 
bleeding 
Thrombocytopenia <100 000 
cells/mm3; HCT rise ≥20% 
DHF (Grade III) As in Grade I or II plus 
circulatory failure [weak pulse, 
narrow pulse pressure (≤20 
mmHg), hypotension, 
restlessness] 
Thrombocytopenia <100 000 
cells/mm3; HCT rise ≥20% 
DHF (Grade IV) As in Grade III plus profound 
shock with undetectable BP and 
pulse 
Thrombocytopenia <100 000 
cells/mm3; HCT rise ≥20% 
Abbreviations: DF: dengue fever, DHF: dengue hemorrhagic fever, WBC: white blood cells, 
HCT: hematocrit 
DHF grade III and IV is dengue shock syndrome (DSS) 
 
Reference: (WHO/SEARO, 2015) 
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1.5 Prevalence and Burden of Dengue Viral Infection 
The global burden of dengue is formidable and represents a growing challenge 
to health authorities. Knowledge of geographical distribution and burden of dengue 
is essential for understanding its contribution to global morbidity and mortality 
burdens in order to determine resource allocation needed for dengue control and in 
evaluating international impact of these control activities (Bhatt et al., 2013).  
1.5.1 Global burden of DVI 
The incidence of dengue has grown dramatically around the world in recent 
decades. However, the actual numbers of dengue cases are underreported or 
misclassified. One recent estimate indicates 390 million dengue infections per year, 
of which 96 million manifests clinically with any severity of disease (Bhatt et al., 
2013). Although the full global burden of the disease is uncertain but number of 
cases reported to WHO has increased from 2.2 million in 2010 to 3.2 million in 
2015. Before 1970, only nine countries had dengue epidemics. Currently, dengue is 
endemic in more than 100 countries in five out of the six WHO regions. Today about 
40% of world`s population live in dengue risk areas. Every year approximately 5 lac 
people with severe dengue require hospitalization and 2.5% of those affected die 
(WHO Fact Sheet 117, 2016). 
1.5.1(a) Dengue in Asia 
The surge in dengue has been most marked in Asia and accounts 75% of global 
dengue burden, costing South-East Asia (SEA) US$1billion annually. It is estimated 
that among 2.5 billion people at risk globally, about 1.8 billion are in Asia. Southeast 
Asia records approximately 2.9 million dengue episodes and 5906 deaths annually, 
with a yearly monetary burden of $950 million (Shepard et al., 2013). Recurrent 
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dengue epidemics in Asia have established hyperendemic areas, often in large and 
heavily populated cities. In South-East Asia, demands of a large health and economic 
burden for dengue control is more challenging than ever. The year 2015 was 
characterized by large dengue outbreaks in Asia, with Philippines and Malaysia 
representing 59.5% and 16% increase in case numbers to the previous year, 
respectively. Alarmingly, spread of Aedes albopictus (a secondary dengue vector) 
from Asia to North America and Europe may result in high disease burden in these 
cooler temperate regions (WHO Fact Sheet – 117, 2017).  
1.5.1(a)(i) Dengue in Malaysia 
The global increase of dengue incidence is also experienced by Malaysia. Since 
the first outbreak in 1902, dengue has become a notifiable infection by 1973 (Mohd-
Zaki et al., 2014). Dengue is among top five notifiable diseases in Malaysia and 
continues to be a formidable public health concern. Since the year 2000, its incidence 
in Malaysia continues to increase from 32 cases per 100,000 populations to 361 cases 
per 100,000 populations in 2014. The incidence of dengue is higher in the age group 
of 15 to 49 years. Most of the cases reported were from urban areas (70–80%) where 
factors such as high density population and rapid development favor dengue 
transmission (Clinical Practice Guidelines - Malaysia, 2015). 
Currently Malaysia is facing worst dengue crisis while some countries in 
South-East Asia (e.g. Philippines & Thailand) have seen decreases in DVI activity in 
2014. Although, number of dengue cases in 2016 (100,028 cases), is less than that 
reported in 2015 (118,325 cases) but still dengue is imposing substantial disease 
burden on health authorities in Malaysia (Figure 1.5) (WPRO-507, 2017). 
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With regards to case fatality rate (CFR), the national target is less than 0.2%. 
The case fatality rate has been reduced from 0.6% in year 2000 to 0.2% in year 2014 
(CPG, 2015). The year 2015 paints a scary picture as highest number of deaths 
(n=322) ever recorded in the country (WPRO-507, 2017). However, 231 dengue 
deaths were reported in 2016 (WPRO-507, 2017) that is comparable to 215 deaths in 
2014 (WPRO-456, 2015). Most of the dengue deaths have been observed among 
individuals with age ≥15 years (Clinical Practice Guidelines - Malaysia, 2015). 
Malaysia is ―hyperendemic‖ with all four dengue virus (DENV) serotypes co-
circulating over the past two decades, 
predominantly DENV1 and DENV2 responsible for the escalating number of cases 
over the recent years (Mudin, 2015). However, a particular dengue virus serotype can 
predominate for at least two years before it is replaced by another serotype. In year 
2013-2014, the predominant serotype had switched twice from DENV-2 to DENV-1 
in February and June 2014 (Clinical Practice Guidelines - Malaysia, 2015). Of the 
estimated, the annual cost for dengue illness (standard errors in parenthesis) in 
Malaysia is US$42.4 (±4.3) including per capita cost US$4.73 for one thousand 
population size (n=1000) with disability adjusted life years (DALYs) equivalent to 
8,324 (Suaya et al., 2009).  
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Figure 1.5: Prevalence of Dengue Infection in Malaysia from 1998 to 2016 
Descriptive note: Data from statistics of Ministary of health Malaysia and World Health Organization
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1.6 Expanded Dengue Syndrome 
In recent years with the geographical spread of dengue illness and with more 
involvement of adults, there have been increasing reports of DVI with unusual 
manifestations, termed as ―Expanded Dengue Syndrome‖ (EDS). These isolated 
organopathies include hepatic, renal, cardiac, respiratory and neurological 
involvements and could be explained as complication of severe profound shock or 
associated with underlying host conditions or coinfections. The involvements of 
various organs are increasingly being reported in DHF, while EDS can also occur 
during DF without any evidence of plasma leakage (WHO/SEARO, 2011).  These 
atypical manifestations were previously termed as ―unusual complications‖ by WHO 
(WHO, 1997; WHO, 2009).  Currently, EDS is new entity incorporated to WHO 
guidelines. The immunopathological mechanisms during dengue infection primarily 
target endothelium, resulting in vascular permeability and coagulation disorders that 
can explain these varied systemic involvements (Gulati et al., 2007).  
Atypical and unusual manifestations of dengue infection are shown in Figure 
1.6. Of these, hepatic complications are more frequent in dengue infection and have 
been well described in various studies (Wahid et al., 2000; Huerre et al., 2001; 
Pancharoen et al., 2002; Seneviratne et al., 2006; Hien et al., 2010). All other 
complications are less frequent and have been reported in few case reports and small 
data series (Solomon et al., 2000; Gulati et al., 2007; Kulratne et al., 2007; Wang et 
al., 2007; Acharya et al., 2010; Raju et al., 2014). However, recently mild to severe 
renal complications have been frequently observed among dengue patients (Lee et 
al., 2009; Khalil et al., 2012; Mehra et al., 2012; Lizarraga & Nayer, 2014).  
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Figure 1.6: Manifestations of Expanded Dengue Syndrome 
Reference: World Health Organization Regional Office for South-East Asia. Comprehensive guidelines for prevention and control of dengue and dengue 
hemorrhagic guidelines, 2011.
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1.7 Renal Complications in Dengue Infection 
The spectrum of renal involvements in dengue infection is described in Figure 
1.6, which includes elevated serum creatinine (SCr), dyselectrolytemia, acute tubular 
necrosis (ATN), hemolytic uremic syndrome, IgA nephropathy, lupus nephritis, 
glomerulonephritis, nephrotic syndrome, proteinuria, and acute kidney injury (AKI). 
Renal involvement is more commonly seen in DHF and DSS, and is an independent 
predictor of mortality (Oliveira & Burdmann, 2015). Several types of dengue 
induced nephropathies are described in this section below. 
1.7.1 Abnormal Urinary Sedimentations 
Urinary sediment is a centrifuged deposit suitable for microscopic examination 
for the presence of cells, casts, bacteria and crystals. Abnormal urinalysis is a general 
feature of kidney involvement in dengue viral infection. Proteinuria, glycosuria, 
ketonuria, occult blood, micro or macroscopic hematuria and presence of tubular 
epithelial cells in urine have been documented among patients with DVI. Urinary 
sedimentations are more prevalent in DHF and DSS (Vachvanichsanong & McNeil, 
2015). 
1.7.2 Glomerulonephritis 
Glomerulonephritis is an inflammation of glomeruli and has been documented 
during or after DVI in both mice and human models. Several mice models infected 
with dengue virus have demonstrated glomerular enlargement, immune-complex 
deposition and proliferative lesions in glomeruli. Immune complex mediated 
glomerulonephritis consists predominantly of immunoglobulin G (IgG), 
immunoglobulin M (IgM) and compliment C3 (Barreto et al., 2004). 
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1.7.3 IgA nephropathy 
IgA nephropathy or Berger`s disease is most common form of 
glomerulonephritis and is characterized by predominant IgA deposition in the 
glomerular mesangium. Mesangial proliferation along with ATN has been 
documented in 15-year-old boy with dengue infection. However, resolution of 
nephropathy has been observed on renal biopsy six weeks later (Upadhaya et al., 
2010).  
1.7.4 Lupus nephritis 
Lupus nephritis is inflammation of kidney caused systemic lupus erythmatosis 
(SLE). Dengue infection evolving into SLE and lupus nephritis has been reported in 
22-year-old woman (Rajadhyaksha, & Mehra, 2012).  
1.7.5 Hemolytic uremic syndrome 
Hemolytic uremic syndrome (HUS) is progressive renal failure and is 
characterized by hemolytic anemia, thrombocytopenia and acute kidney injury. HUS 
with renal recovery has been previously reported among dengue patients (Oliveira & 
Burdmann, 2015). 
1.7.6 Acute Kidney Injury (AKI) 
AKI, previously known as acute renal failure (ARF), is sudden onset (within a 
few hours or a few days) of renal dysfunction primarily characterized by elevated 
SCr and reduction in glomerular filtration rate (GFR). It encompasses a wide 
spectrum of injury to the kidneys, not just kidney failure. AKI has been reported to 
affect from 13% to 18% of hospitalized patients and 1% to 25% of intensive care unit 
 24 
(ICU) patients. AKI is associated with adverse outcomes and high mortality rates 
ranging from 25% to 80% (KDIGO, 2012; Bellomo et al., 2012). 
1.7.6(a) Clinical Manifestations and Etiology of AKI 
Clinical manifestations and causes of AKI are described in Table 1.5. Sign and 
Symptoms of AKI are associated with the disturbances of normal kidney functions. 
However, on the basis of etiology, AKI is divided into three categories including pre-
renal AKI (due to decreased renal perfusion, often because of volume depletion), 
intra-renal or intrinsic AKI (due to processes within the kidney) and post-renal AKI 
(caused by inadequate drainage of urine crystals to the kidneys) (Greenberg & 
Cheung, 2005).  
